Clinical Response to Neoadjuvant Immunotherapy Combined with Targeted Therapy and Chemotherapy in Oral Squamous Cell Carcinoma: Experience in Three Patients
Yu Tian,Lei Zhang,Nenghao Jin,Zhiyi Wan,Henghui Zhang,Haizhong Zhang,Lei Zhang
DOI: https://doi.org/10.2147/OTT.S355349
IF: 4
2022-04-08
OncoTargets and Therapy
Abstract:Yu Tian, 1, 2, &ast Lei Zhang, 3, &ast Nenghao Jin, 1, 2, &ast Zhiyi Wan, 3 Henghui Zhang, 4, 5 Haizhong Zhang, 2 Lei Zhang 2 1 Department of Stomatology, Medical School of Chinese PLA, Beijing, People's Republic of China; 2 Department of Stomatology, The First Medical Center, Chinese PLA General Hospital, Beijing, People's Republic of China; 3 Department of Medicine, Genecast Biotechnology Co., Ltd, Wuxi, Jiangsu, People's Republic of China; 4 Biomedical Innovation Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, People's Republic of China; 5 Ninth School of Clinical Medicine, Peking University, Beijing, China; School of Oncology, Capital Medical University, Beijing, People's Republic of China &astThese authors contributed equally to this work Correspondence: Haizhong Zhang; Lei Zhang, Department of Stomatology, The First Medical Center, Chinese PLA General Hospital, No. 28, Fuxing Road, Beijing, People's Republic of China, Tel/Fax +86 1066938316, Email ; Immune checkpoint inhibitors (ICIs) pembrolizumab and nivolumab have been approved for the treatment of head and neck squamous cell carcinoma (HNSCC) and used in neoadjuvant immunotherapy in clinical trials. However, combination of ICIs with targeted therapy and chemotherapy was rarely used in pre-surgical HNSCC patients. Herein, we encountered three cases of patients with oral squamous cell carcinoma (OSCC) who all had good responses to neoadjuvant immunotherapy (anti-PD-1 inhibitors) combined with nimotuzumab (anti-EGFR monoclonal antibody) plus paclitaxel. Both Case 1 and Case 2 underwent the same neoadjuvant therapeutic combination (nivolumab, nimotuzumab and paclitaxel) and exhibited a marked tumor shrinkage even complete disappearance by radiological evaluation. Moreover, pathological response was observed in post-surgical tissues of Case 1. Additionally, Case 3 with tongue squamous cell carcinoma also had satisfactory tumor regression (complete healing of his tongue ulcer upon treatment) after receiving similar neoadjuvant therapy with sintilimab (another PD-1 inhibitor), nimotuzumab and paclitaxel. We characterized their potential causes behind favorable treatment outcomes. While there were differences in driver mutations and tumor mutation burden (TMB) identified in pre-treatment tumor tissues among the three patients, numerous CD68+ (macrophages) infiltrates were common for all the cases. Of note, the majority (> 80%) of the total macrophages were molecularly defined as PD-L1-positive macrophages. Given the high expression of PD-L1 in macrophages is associated with better immunotherapy outcomes, we propose that the high proportion of CD68+PD-L1+ cells in total macrophages alone could serve as a promising biomarker for neoadjuvant immunotherapy in combination with other therapies in HNSCC. Keywords: head and neck squamous cell carcinoma, oral squamous cell carcinoma, neoadjuvant immunotherapy, PD-L1, CD68, macrophage Head and neck cancers usually arise from the squamous cells in oral cavity, oropharynx, hypopharynx, or larynx, being referred to as head and neck squamous cell carcinoma (HNSCC). While patients with locoregionally advanced HNSCC accounting for approximately 60% of all HNSCC cases tend to receive multimodal therapies including surgery and chemoradiotherapy, over half of them experience recurrence. The current first-line standard of care treatment for recurrent or metastatic HNSCC is the combination of cetuximab, platinum and 5-fluorouracil (5-FU), which gives rise to the median overall survival (OS) of less than 10 months. 1 Immune checkpoint inhibitors (ICIs) targeting PD-1 (programmed cell death protein 1) or PD-L1 (programmed death-ligand 1) have revolutionized the treatment paradigm for various cancers. In 2016, two immunotherapeutic agents, PD-1 monoclonal antibodies, nivolumab and pembrolizumab were approved by the US Food and Drug Administration (FDA) for the treatment of patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (R/M HNSCC) refractory to platinum-based therapy. In 2019, the FDA approved pembrolizumab combined with platinum and fluorouracil for the first-line treatment of patients with metastatic or unresectable, recurrent HNSCC, while pembrolizumab monotherapy is indicated for the first-line treatment of PD-L1-positive (CPS > 1) patients with metastatic or unresectable, recurrent HNSCC based on the results of KEYNOTE-048. 2 In addition to immunotherapy, nimotuzumab targeted therapy, an EGFR (epidermal growth factor receptor)-targeted monoclonal IgG1 antibody, has been approved for the treatment of HNSCC in several countries inc -Abstract Truncated-
oncology,biotechnology & applied microbiology